Glenmark

Glenmark Standalone March 2025 Net Sales at Rs 2,009.49 crore, down 6.46% Y-o-Y

Glenmark Consolidated December 2024 Net Sales at Rs 3,387.55 crore, up 35.14% Y-o-Y

Aurobindo Pharma, Glenmark recall products in US

As per the latest Enforcement Report of US Food and Drug Administration (USFDA), Aurobindo Pharma USA Inc, a subsidiary of Hyderabad-based drug maker, is recalling over 1 lakh bottles of Cinacalcet tablets in multiple strengths.

Glenmark Consolidated September 2024 Net Sales at Rs 3,433.80 crore, up 7.06% Y-o-Y

Glenmark Standalone September 2024 Net Sales at Rs 2,636.10 crore, up 18.03% Y-o-Y

Glenmark Pharmaceuticals PAT at Rs 354 crore in September quarter

The company reported a consolidated loss after tax of Rs 180.3 crore in the same quarter last fiscal, Glenmark Pharmaceuticals said in a regulatory filing

Domestic formulations biz expected to grow 9-10% over next decade: Glenmark

The domestic formulations market is estimated to be at Rs 2 lakh crore, with a growth rate of 11 percent over the past two decades

Glenmark Consolidated June 2024 Net Sales at Rs 3,244.19 crore, down 4.63% Y-o-Y

Glenmark Standalone June 2024 Net Sales at Rs 2,329.54 crore, up 8.63% Y-o-Y

Glenmark Consolidated March 2024 Net Sales at Rs 3,062.95 crore, down 9.21% Y-o-Y

Glenmark Standalone March 2024 Net Sales at Rs 2,148.22 crore, up 10.79% Y-o-Y

Glenmark Pharma Q4 net loss widens to Rs 1,239 crore

Glenmark Q4: Revenue rose two percent from the previous year to Rs 3,063 crore, from Rs 3,000.5 crore in the same period a year ago

Glenmark unit ties up with BeiGene to market cancer drugs in India

Glenmark Specialty SA, a unit of Mumbai-based drug maker, has inked exclusive marketing and distribution agreement with BeiGene.

Glenmark gets USFDA nod for generic ophthalmic solution

The final approval by the US Food & Drug Administration (USFDA) is for brimonidine tartrate and timolol maleate ophthalmic solution of strength 0.2 per cent/0.5 per cent, Glenmark said in a statement.

Lupin, Glenmark recall drugs in US market: USFDA

As per the latest Enforcement Report by the US Food and Drug Administration (USFDA), Lupin is recalling 26,352 bottles of Rifampin Capsules (300 mg), an antibiotic medication in the US market.

Lupin, Glenmark, Natco recall products from US markets

Lupin recalled 26,352 bottles of Rifampin capsules, used in the treatment of tuberculosis

Glenmark Consolidated December 2023 Net Sales at Rs 2,506.70 crore, down 27.63% Y-o-Y

Glenmark Standalone December 2023 Net Sales at Rs 1,365.10 crore, down 36.84% Y-o-Y

Nirma Rs 1,343 crore open offer to buy more stake in Glenmark Life Sciences to start on Feb 15

The opening date (commencement of the tendering period) for the open offer has been fixed on February 15, 2024, and will close on February 29, 2024, as per the letter of offer, the letter said.

Glenmark, Sun Pharma recall drugs in the US over labelling and manufacturing concerns, confirms USFDA

Glenmark Pharmaceuticals recalled 37,200 bottles of Indomethacin capsules and Sun Pharma recalled 2016 bottles of buPROPion Hydrochloride Extended-Release Tablets.

Dr Reddy's, Glenmark recall products in US due to manufacturing issues

In its latest enforcement report, the US health regulator said Princeton-based Dr Reddy’s Laboratories, Inc., a unit of the Hyderabad-based drug firm, is recalling 1,656 bottles of Montelukast sodium tablets.

Glenmark Standalone September 2023 Net Sales at Rs 2,233.42 crore, up 1.14% Y-o-Y

Glenmark Consolidated June 2023 Net Sales at Rs 3,401.60 crore, up 22.48% Y-o-Y

Glenmark Standalone June 2023 Net Sales at Rs 2,144.38 crore, up 12.16% Y-o-Y

Lupin may spin off API business as part of business recast to unlock value

Glenmark Pharma had undergone a similar exercise in May 2019, when it spun off its API business into a new entity called Glenmark Life Sciences, which made its public market debut in August 2021